

**Hemodialysis – Update**

# Hemodialysis Adequacy

연세의대

박 정 탁

### Adequate dialysis



- Dialysis treatment is defined **“adequate”** when it permits the patients
  - To be fully rehabilitated
  - To have a satisfactory nutritional intake and a sufficient production of RBCs
  - To maintain normal blood pressure values
  - To prevent the development of neuropathy
- Better than adequate dialysis, better than adequate doctors**

*De Palma JR et al. N Engl J Med 1971;285:353-354*

### Introduction

**Dose of dialysis and clinical outcome**  
**Methods for quantification**  
**Clinical guidelines**

### Introduction




### Accumulation of uremic toxins

Molecules	Molecular weight	Example
Small water-soluble compounds	<500 Da	Urea, asymmetric dimethylarginine, creatine, creatinine, guanidine, hypoxanthine, uric acid, and oxalate
Protein-bound solutes	Variable	p-cresol, phenol, 3-deoxyglucosone, hippuric acid, indoxyl sulfate, melatonin, leptin, retinol-binding protein, and homocysteine
Middle molecules	>500 Da	$\beta_2$ -microglobulin, parathyroid hormone, and advanced glycosylation end products

*J Korean Med Assoc. 2013 Jul;56(7):583-591.*

### Dialysis dose and outcome



### Dose of dialysis and clinical outcome

### Dose of dialysis and clinical outcome

- 1981' National Cooperative Dialysis Study (NCDS)
- 1983' Mechanistic Analysis of the NCDS
- 1996' United States Renal Data System (USRDS)
- 2002' HEMO study


### 1981' National Cooperative Dialysis Study (NCDS)

- The First Attempt to Define Adequate Hemodialysis Dose.
- The National Institute of Health (NIH)-sponsored conference on Adequacy of Dialysis held in 1975
- ✓ **Conclusion:**
  - ✓ "A carefully controlled multicenter cooperative study was required to determine if quantitative relationships between residual morbidity and the magnitude of dialysis prescribed could be established."

*Lowrie EG et al. N Engl J Med 1981;305:1176-1181*


### 1981' National Cooperative Dialysis Study (NCDS)

- **TAC<sub>urea</sub>: The Time-Averaged BUN Concentration**
  - An integrated parameter computed as the mean BUN during a full dialysis cycle
- Patient characteristics
- Urea generation
- Dialysis time
- Dialyzer urea clearance
- Total number of treatments




*Lowrie EG et al. N Engl J Med 1981;305:1176-1181.*

### 1981' National Cooperative Dialysis Study (NCDS)



*Lowrie EG et al. N Engl J Med 1981;305:1176-1181.*

### 1981' National Cooperative Dialysis Study (NCDS)



Lowrie EG et al. N Engl J Med 1981;305:1176-1181


### 1981' National Cooperative Dialysis Study (NCDS)

- The most important lessons from NCDS
  - ✓ The importance of small molecule clearance, which forms the basis of current standards of adequacy
  - ✓ The delivered dose of dialysis can and should be quantified.
- Limitations:**
  - Iteration with a computerized model.
  - Difficult to be applied to daily practice
  - A low urea value fails to distinguish the well dialyzed patients from the malnourished one.

Laird NM et al. Kidney Int 1983;23 (Suppl 13):S101-S106.

### 1983' Mechanistic Analysis of the NCDS

- The most significant correlate with outcome was BUN (TAC<sub>urea</sub>); the second most significant influence on outcome was the urea generation rate (nPCR).



Laird NM et al. Kidney Int 1983;23 (Suppl 13):S101-S106.

### 1983' Mechanistic Analysis of the NCDS


- Thus, Kt/V is a basic, generalizable dialysis parameter and serves as the basis of the mechanistic analysis reported here (formal urea kinetic modeling).

$$Kt/V \approx -\ln[1 - (0.49 \times nPCR - 0.16) / \text{pre-dialysis BUN}]$$



Laird NM et al. Kidney Int 1983;23 (Suppl 13):S101-S106.

### 1983' Mechanistic Analysis of the NCDS




Gotch FA et al. Kidney Int 1985;28:526-534.

### 1996' United States Renal Data System (USRDS)

- United States Renal Data System
- Random national sample of 2,311 patients from 347 dialysis units
- Delivered hemodialysis dose to mortality
- Adjustment for extensive comorbidity/risk factors

Kidney International, Vol. 50 (1996), pp. 550-556.

### 1996' United States Renal Data System (USRDS)



Kidney International, Vol. 50 (1996), pp. 550-556.

### 1996' United States Renal Data System (USRDS)

- Dialysis dose is related to mortality.
- Clearance estimated by Kt/V clearly reflects outcome.
- Mortality risk was lower by 7% with each 0.1 higher level of delivered Kt/V
- No further significant improvement in mortality above Kt/V > 1.3 (or a URR > 70%).

Kidney International, Vol. 50 (1996), pp. 550-556.


### 2002' HEMO study

- Effect of dialysis dose and membrane flux in maintenance hemodialysis
- First large-scale RCT on HD adequacy target
- March 1995 to Oct 2000
- 1846 patients from 72 dialysis units in US
- Mean duration of dialysis before enrollment : 3.7years
- Mean follow up : 2.84 years

N Engl J Med. 2002 Dec 19;347(25):2010-9.


### 2002' HEMO study

- Randomized 2 x 2 factorial design clinical trial




N Engl J Med. 2002 Dec 19;347(25):2010-9.

### 2002' HEMO study



The primary outcome was not significantly influenced by treatment assigned for dose of dialysis or for the flux of the dialysis membranes used. N Engl J Med. 2002 Dec 19;347(25):2010-9.

### 2002' HEMO study



Depner et al, Kidney Int 2004

### 2002' HEMO study

- In patients receiving thrice-weekly HD a higher dose of dialysis does not significantly improved survival.
- Increase of the dialysis dose above the currently recommended minimum dose do not improve patients outcome.
- It is possible that a much higher dose of dialysis and higher convection may improve outcome.

*N Engl J Med. 2002 Dec 19;347(25):2010-9.*

## Methods for quantification


### Urea: Surrogate or toxin

- **Ideal markers of dialysis dose.**
  - 1. Easily measured
  - 2. Eliminated by dialysis
  - 3. Toxicity related to renal failure
  - 4. Representative of other potential toxins that accumulate in renal failure
- **Urea as surrogate solute of choice**
  - Abundance in plasma
  - Technically easy to measure
  - Similar volume distribution to total body water
  - Urea clearance correlated with outcomes

*Kidney International (1997) 52, Suppl. 62, S96-S100.*

### Urea reduction ratio

- **URR(urea reduction ratio)**  
=  $\frac{\text{Predialysis BUN} - \text{postdialysis BUN}}{\text{Predialysis BUN}}$




- **Draw backs**
  - post-dialysis rebound
  - Intradialytic urea generation
  - Effect of ultrafiltration

*Kidney International (1999) 56, 754-755.*

### Urea reduction ratio


- **URR impacts on patient survival**



*Kidney International, Vol. 50 (1996), pp. 550-556.*

### Single-pool KT/V

- **preferred method for measurement of the delivered dose**



*Kidney International (1999) 56, 754-755.*

### Single-pool KT/V

K: the dialyzer blood water urea clearance (L/hour)

T: Treatment session length (hours)

Volume of plasma cleared (L)

KT/V

The distribution volume of urea (L)

(A dimensionless ratio, KT over V)

Kidney International (1999) 56, 754-755.

### Single-pool KT/V

KT/V  
(A dimensionless ratio, KT over V)

### Single-pool KT/V

- $Kt/V = -\ln(R - 0.008 \times t) + (4 - 3.5 \times R) \times \Delta BW / BW$ 
  - R: the ratio of postdialysis BUN to predialysis BUN
  - t: time of dialysis in hours
  - BW: body weight.
- URR and spKt/V are mathematically linked
- Intradialytic urea generation
- Effect of ultrafiltration
- Neither URR nor Kt/V is superior as a measure of outcome

Daugirdas JT. J Am Soc Nephrol 1993;4:1208-1213

### Double-pool KT/V

- Equilibrated Kt/V
- Postdialysis rebound; urea diffuses from sequestered tissues

Pre

Post

### Single-pool KT/V

- $spKt/V = -\ln(R - 0.008 \times t) + (4 - 3.5 \times R) \times \Delta BW / BW$ 
  - R: the ratio of postdialysis BUN to predialysis BUN
  - t: time of dialysis in hours
  - BW: body weight
- $eKt/V = -\ln(Req - 0.008 \times t) + (4 - 3.5 \times R) \times \Delta BW / BW$ 
  - Req: the ratio of equilibrated BUN to predialysis BUN
- eKt/V is typically 0.2 units lower than the spKt/V

CALCULATORS AND MODELING AIDS

**What is the KtV, PCRn, and V (single and double-pool)?**

Enter Patient Data. All blanks must be filled in!

12345678 Patient ID Number

Dialysis schedule and blood sampling day of week:  
 3week(E or T)  3week(W or Th)  3week(F or Sa)  
 2week(after long interval)  2week(before long interval)

67 Pre-dialysis weight

65 Post-dialysis weight  Kilograms  Lbs

170 Height  inches  cm

55 Age  Male  Female

2 Residual urea clearance (ml/min)

---

Enter Treatment Data

90 Pre BUN

35 Post BUN  mg/dl  mmol/liter

Postdialysis blood sample:  
 no slow flow  15-20 sec slow flow  2 min slow flow

Vascular access (arterial, venous):  
 A.V  V.V

240 Session length (minutes)

250 Blood flow rate

Dialysate flow rate:  
 500  600  800

Urea Kinetics Calculator: Results

*These were your inputs*

ID = 12345678  
 Height in inches = 170  
 Dialyzer model = Polyflux 145  
 No model given: user input K0A = 0  
 Predialysis BUN = 90  
 Postdialysis BUN = 35  
 Blood flow rate (ml/min) = 250  
 Dialysate flow rate (ml/min) = 500  
 Patient gender = male  
 Session length (min) = 240  
 Predialysis weight (kg) = 67  
 Postdialysis weight (kg) = 65  
 Residual urea clearance (Kru, ml/min) = 2

---

*These are your results*

*Single-pool modeling outputs:*  
 Urea reduction ratio (as percent) = 61.11  
 Treatment KtV = 1.11  
 KtV adjusted for Kru = 1.25  
 Estimated Kd (dialyzer blood water urea clearance incl. Qf, ml/min) = 188.5  
 PCRn (includes Kru if entered, g/kg/day) = 1.52  
 TAC urea (mg/dL) = 66.5

*Double-pool modeling outputs:*  
 Treatment KtV = 0.972  
 KtV adjusted for Kru = 1.11  
 PCRn (includes Kru if entered, g/kg/day) = 1.41

## Clinical guidelines



### KDOQI Hemodialysis Adequacy Guidelines 2006

- ### Minimally Adequate Hemodialysis
- The delivered dose of HD should be measured at regular intervals no less than monthly. (A)
  - The minimally adequate dose of HD given 3 times per week to patients with  $K_r$  less than 2 mL/min/1.73 m<sup>2</sup> should be an *spKt/V (excluding RKF) of 1.2 per dialysis*. For treatment times less than 5 hours, an alternative minimum dose is a URR of 65%. (A)
  - The target dose for HD given 3 times per week with  $K_r$  less than 2 mL/min/1.73 m<sup>2</sup> should be an *spKt/V of 1.4 per dialysis* not including RKF, or URR of 70%. (A)

- ### Methods for Predialysis Blood Sampling
- Both samples (predialysis and postdialysis) should be drawn during the same treatment session. (A)
  - The risk of underestimating predialysis BUN level because of saline dilution or by sampling the blood after treatment has begun should be avoided. (A)

### Methods for Predialysis Blood Sampling

- The risk of underestimating the postdialysis BUN level because of access recirculation (AR) should be avoided by
  - First slowing the blood flow through the dialyzer to a rate at which AR is expected to be minimal (**100 ml/min**) for a period long enough to ensure that unrecirculated blood has advanced to below the sampling port (**usually 15 seconds**). (A)

A → B: usually within 20 seconds, less than 1 min  
 B → C: 2 to 3 minutes after slowing the pump  
 C → D: 3 minutes to 30 - 60 minutes

### Points to remember

---

- Measuring the clearance of solutes that accumulate in patients with uremia has become the mainstay for calculating the dose of dialysis and determining its adequacy as delivered.
- The minimally adequate dose of HD given 3 times per week to patients with  $K_r$  less than 2 mL/min/1.73 m<sup>2</sup> should be an spKt/V (excluding RKF) of 1.2 per dialysis. For treatment times less than 5 hours, an alternative minimum dose is a URR of 65%.
  - Preferably, the target dose should be an spKt/V of 1.4 per dialysis not including RKF, or URR of 70%.
- When dialysis adequacy is assessed by using predialysis and postdialysis BUN measurements, blood samples should be drawn by using certain acceptable procedures.